In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.
Sign Up to like & getrecommendations! Published in 2019 at "Microbial drug resistance"
DOI: 10.1089/mdr.2018.0410
Abstract: Tedizolid activity was compared with other agents with oral and intravenous formulations against community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Tedizolid (MIC50/90, 0.12/0.12 mg/L; 100.0% susceptible) was the most potent agent tested against CA-MRSA and subsets from adult… read more here.
Keywords: acquired methicillin; 100 susceptible; resistant staphylococcus; community acquired ... See more keywords
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Microbiology"
DOI: 10.1128/jcm.02449-21
Abstract: Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for Candida spp. and rezafungin. The activities of rezafungin and… read more here.
Keywords: 100 susceptible; susceptible candida; candida; mic50 mic90 ... See more keywords